Oragenics Inc. · AMEX:OGEN
Oragenics — Investor Presentation (October 2022)
14 slides from Oragenics's investor presentation, Oct 3, 2022
Slide 1: Corporate Presentation
‘Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information curren
Slide 3: Differentiated Intranasal COVID Vaccine: NT-CoV2-1
Kim Murphy, CEO, has more than 25 years’ experience leading vaccine franchises at GSK, Merck and Novartis and executed 4 multiple successful commercial launches Experienced L Differentiated Intranasal COVID Vaccine: NT-CoV2-1 Non-viral platform with adjuvant; rapid production for emerging variants ‘
Slide 4: Intranasal COVID-19 Vaccine Overview
Intranasal COVID-19 Vaccine Overview + Lead Asset: NT-CoV2-1 * Licensed from NIH - two-proline substitution of SARS-CoV-2 spike protein * Currently in pivotal toxicology study and expected to enter clinical studies in 1Q22 + NT-CoV2-1 Non-Viral Intranasal Vaccine Differentiation and Advantages - Pat
Slide 5: Licensed 2P spike protein design and platform
+ Licensed “2P” spike protein design * Highly de-risked , (Pfizer/BioNTech, 4 Moderna) A National Institute of Allergy and Infectious Diseases + Patient-friendly + Potential to reduce infection and transmission * Sequence -> Ph1 GMP DS in 12 wks * Multiple VOC spike antigens » produced Zz IgA Ab (mu
Slide 6: Anti-Spike IgG titers in hamsters
Day 20 Post-Dose 1 cd 105 9 > wee = 10% ie 0883 Se 28 § § 10° oe0 ee ge EO 102 2 ed Gs cee a ne Veh. BDX301 BDX301 BDX301 Alone +5ug +15yg Ag Ag Day 35, 2 Weeks Post-Dose 2 eRe on 8588 > 6 2 § 10% 2aake ae oO lw = 8 § 10> EE 28 a Zo 10? < 101 — ‘Veh. BDX301 BDX301 BDX301 Alone +5pg +15ug Ag Ag Anti-
Slide 7: Efficacy against SARS-CoV-2 challenge in hamsters
_t Lungs Nasal Turbinates 7 T 26 = 6 3 5 see sé ES* rs¢ fa 3 fa 3 >e >e 8 2 8 2 = = 0. 0 $$ 2-4-2 ee Veh. BDX301 BDX301 BDX301 Veh. BDX301 BDX301 BDX301 Alone +5yg +15 yg Alone +5yg +1549 Ag Ag Ag Ag Efficacy of SmT1v3 and BDX301 formulations against SARS-CoV-2 viral challenge in hamsters. Syrian Go
Slide 8: Intranasal COVID-19 Vaccines
Intranasal COVID-19 Vaccines Potential benefits of intranasal COVID vaccines ¢ Intranasal vaccines may address limitations of current vaccines — Waning efficacy requiring third (and fourth) doses for new variants of concern (VOC) — Transmission remains a concern due to high nasopharyngeal viral load
Slide 9: COVID-19 Vaccine Competition
COVID-19 Vaccine Competition Competitive landscape for intranasal COVID vaccines Organiza Orga n Type Vaccine Ty, Stage Com Ss Live chimpanzee Known AEs (blood clots) may hinder vase Zanes Glepallinerma adenovirus vector meUaseat approval & acceptance in US/EU . . . Live attenuated Hard to establish
Slide 10: Milestone Timeline
10 Milestone Timeline Q Interim Toxicology Data Q Expected Start Phase 1 Q Pursuing CTA/IND parallel path First-in-Human NT-CoV2-1 O Expected Regulatory Feedback Ongoing business development Goal to partner post Phase 7 f oN Q Expected Final Toxicology Data Q Expected File CTA/IND Q Expected Phase 1
Slide 11: New Management Objectives
New,Management Objectives 1. Communicating and Achieving Milestone Timelines Through the synergistic execution of new management objectives 2. Secure Capitalization for Sustained Operations 3. Building Visibility & Credibility Opportunistic Business 1. Capital Markets Model Sect pital for Fut Develo
Slide 12: Common Stock Outstanding 117,304,809
Common Stock Outstanding 117,304,809 Series A and Series B Convertible Preferred cat (As Converted) 1,351,700 Warrants (WAEP $1.42) 18,040,572 Reserved for issuance under stock 17,252,710 incentive plan Total 153,949,791 Le]
Slide 13: heal
heal Experiences ane Le Differentiated Intranasal COVID Vaccine: NT-CoV2-1 Kim Murphy, CEO, has more than 25 years’ experience leading vaccine franchises at GSK, Merck and Novartis and executed multiple successful commercial launches Non-viral platform with adjuvant; rapid production for emerging va
Slide 14: For More Information
For More Information / Corporate R Investors: . hael Sullivan \ Tirth T. Patel, Vice President ~ “Chief Financial Officer —~ LHA Investor Relations < 813.286.7900 ext. 246 2 T: 212.201.6614 | tpatel@lhai.com ~ / msullivan@ oragenics.com ’ le \ NYSE American: OGEN